Degron Therapeutics vs ONCOMATRYX
Degron Therapeutics vs ONCOMATRYX, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Degron Therapeutics is on 62/100 and ONCOMATRYX on 50/100.
Where each one leads
Degron Therapeutics
- our overall score: 62/100 against 50/100
ONCOMATRYX
- agent readiness: 36/100 against 27/100
- headcount: 36 against 24
- funding raised: $107M against $40.0M
- LinkedIn following: 5,170 against 1,380
At a glance
| Measure | Degron Therapeutics | ONCOMATRYX |
|---|---|---|
| What it is | Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines. | Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies. |
| Category | Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare | Biotechnology, Pharmaceuticals, Healthcare, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Services |
| Founded | 2020 | 2009 |
| Headquarters | San Diego, USA | Derio, Spain |
| Status | Active | Active |
Size, funding and growth
| Measure | Degron Therapeutics | ONCOMATRYX |
|---|---|---|
| Employees | 24 | 36 |
| Total funding | $40.0M | $107M |
| Latest round | Series A Extension | Funding Round |
| Valuation | $1.1B | Not published |
| LinkedIn followers | 1,380 | 5,170 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Degron Therapeutics | ONCOMATRYX |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 62/100 | 50/100 |
| Traction | Not published | 56/100 |
| Team | 24/100 | 30/100 |
| Search visibility | 57/100 | 37/100 |
| Quality | Not published | 55/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (27/100) | F (36/100) |
| Domain ratingLink authority, 0-100 | 24/100 | 26/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Degron Therapeutics | ONCOMATRYX |
|---|---|---|
| Hosting | Self Managed | Self Managed |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Analytics 4 |
Degron Therapeutics vs ONCOMATRYX: common questions
Which is better, Degron Therapeutics or ONCOMATRYX?
On our 0-100 score Degron Therapeutics rates higher (62/100 against 50/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.
How do Degron Therapeutics and ONCOMATRYX compare on the numbers?
Degron Therapeutics leads on our overall score (62/100 against 50/100). ONCOMATRYX leads on agent readiness (36/100 against 27/100), headcount (36 against 24), funding raised ($107M against $40.0M), LinkedIn following (5,170 against 1,380).
Read the full Degron Therapeutics review and pricing or the ONCOMATRYX review and pricing. You can also browse other Degron Therapeutics alternatives we track.